S. Spencer

发表

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

D. Matei, J. Ledermann, J. Barrett, 2014, The Lancet. Oncology.

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

D. Matei, J. Ledermann, C. Scott, 2016, British Journal of Cancer.

2759 Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib

M. Friedlander, U. Matulonis, S. Kaye, 2015 .

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

R. Plummer, A. Italiano, L. Dirix, 2018, Advances in Therapy.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

B. Gilks, J. Ledermann, A. Gutin, 2015, British Journal of Cancer.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

D. Matei, J. Ledermann, C. Scott, 2016, The Lancet. Oncology.

Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Werner Meier, Ignace Vergote, Philipp Harter, 2016, Cancer.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

D. Matei, J. Ledermann, J. Barrett, 2014 .

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

B. Gilks, J. Ledermann, A. Gutin, 2018, British Journal of Cancer.

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

James X. Sun, Roman Yelensky, Zhongwu Lai, 2017, Oncotarget.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

D. Schadendorf, R. Dummer, A. Arance, 2013, The Lancet. Oncology.

Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy

Helen Moore, I. González-García, S. Spencer, 2021, CPT: pharmacometrics & systems pharmacology.

Global Burden of Disease 2010 Study: A personal reflection

S. Spencer, 2013, Global cardiology science & practice.

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

N. Reinmuth, Haiyi Jiang, L. Paz-Ares, 2022, JTO clinical and research reports.

MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

Y. Shrestha, L. Paz-Ares, M. Garassino, 2021, Journal of Thoracic Oncology.

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

D. Matei, J. Ledermann, C. Scott, 2018, British Journal of Cancer.

Lessons from the PURE study

S. Spencer, 2014, Global cardiology science & practice.

885PDHEALTH-RELATED QUALITY OF LIFE (HRQOL) DURING OLAPARIB MAINTENANCE THERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC) AND A BRCA MUTATION (BRCAM).

D. Matei, J. Ledermann, C. Scott, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

D. Cunningham, J. Bar, G. Goss, 2014, Clinical colorectal cancer.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy

J. Ledermann, G. Rustin, U. Matulonis, 2015 .

Olaparib combined with abiraterone in patients with metastatic prostate cancer: Safety run-in from a phase II study.

N. Clarke, S. Spencer, R. Shepard, 2015 .

Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

D. Matei, J. Ledermann, C. Scott, 2015 .

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib

P. Hoff, S. Spencer, S. Morgan, 2014, British Journal of Cancer.

Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

D. Cunningham, J. Bar, G. Goss, 2014, Clinical colorectal cancer.